PARIS, Aug 3 (Reuters) – French drugmaker Sanofi (SASY.PA) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (TBIO.O), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson said.Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.
Construction materials release chemicals, the weather inside matters, and smart material choices make a real…
The global sky-based communication market was valued at USD 172.3 million in 2025 and is…
Global markets in early 2026 are being reshaped by shifting investment strategies, geopolitical developments, and…
Global investors are shifting focus in 2026 from high-flying AI stocks to undervalued sectors and…
The global AI accelerator chips market was valued at USD 120.2 billion in 2025 and…
A new campaign by Aveeno and TOGETHXR brings together iconic female athletes to redefine strength,…